Recruiting
Phase 2
Phase 3

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Sponsor:

argenx

Code:

NCT05523167

Conditions

Active Idiopathic Inflammatory Myopathy

Myositis

Dermatomyositis

Polymyositis

Immune-Mediated Necrotizing Myopathy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

EFG PH20 SC

PBO

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information